Home » Stocks » CNSP

CNS Pharmaceuticals, Inc. (CNSP)

Stock Price: $2.02 USD 0.10 (5.21%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $2.04 +0.02 (0.99%) Jan 19, 7:59 PM
Market Cap 45.80M
Revenue (ttm) n/a
Net Income (ttm) -8.98M
Shares Out 16.48M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $2.02
Previous Close $1.92
Change ($) 0.10
Change (%) 5.21%
Day's Open 1.96
Day's Range 1.91 - 2.04
Day's Volume 2,776,773
52-Week Range 1.45 - 4.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 3 weeks ago

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

Other stocks mentioned: AMRS, CYRN, MREO, NGD, RARE, XELA
GlobeNewsWire - 3 weeks ago

HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc . (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for pri...

PRNewsWire - 1 month ago

HOUSTON, Dec. 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...

PRNewsWire - 1 month ago

HOUSTON, Dec. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...

GlobeNewsWire - 1 month ago

HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for prim...

PRNewsWire - 3 months ago

HOUSTON, Oct. 9, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...

GlobeNewsWire - 3 months ago

HOUSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development ...

PRNewsWire - 4 months ago

HOUSTON, Sept. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

GlobeNewsWire - 4 months ago

Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the develo...

PRNewsWire - 4 months ago

HOUSTON, Aug. 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

PRNewsWire - 4 months ago

HOUSTON, Aug. 20, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

HOUSTON, July 22, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...

PRNewsWire - 6 months ago

HOUSTON, July 8, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...

PRNewsWire - 7 months ago

HOUSTON, May 28, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...

PRNewsWire - 7 months ago

HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...

PRNewsWire - 7 months ago

HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...

Market Watch - 8 months ago

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company.

Other stocks mentioned: MBRX
PRNewsWire - 8 months ago

HOUSTON, May 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...

Market Watch - 8 months ago

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday they did not solicit or have any advance knowledge about claims made by third parties about drug candi...

Other stocks mentioned: MBRX
Benzinga - 9 months ago

CNS Pharmaceuticals (NASDAQ: CNSP) shares are trading higher on Monday. The company announced that independent research from the University of Frankfurt showed that an active compound in WP112...

Benzinga - 9 months ago

Nano-cap biotech CNS Pharmaceuticals Inc (NASDAQ: CNSP), which develops treatments for cancers of the brain and central nervous systems, said Monday that it has struck an agreement with Canada...

Seeking Alpha - 10 months ago

CNS Pharmaceuticals, Inc. (CNSP) Management on Q4 2019 Results - Earnings Call Transcript

About CNSP

CNS Pharmaceuticals, a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. CNS Pharmaceuticals, Inc. was founded in 201... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 2019
CEO
John Michael Climaco Esq., J.D.
Employees
3
Stock Exchange
NASDAQ
Ticker Symbol
CNSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CNSP stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 271.29% from the latest price.

Price Target
$7.50
(271.29% upside)
Analyst Consensus: Buy